Indrayani Biotech has secured a two-month extension from the Registrar of Companies to hold its upcoming Annual General Meeting.

This extra time is necessary because the company is currently planning a capital restructuring, which includes a Rights Issue and requires multiple approvals.

For retail investors, this means management is focused on completing these strategic corporate actions properly before presenting the annual financials to shareholders.

While the meeting is delayed, the groundwork for capital expansion is actively progressing behind the scenes.